Diffusion imaging is not limited to basic measures like FA (fractional anisotropy), or even fiber tractography; other microstructure elements can be of major interest. Free-water is a telling example.

Imeka’s diffusion imaging tools are able to measure extracellular water fraction (free-water), which in turn serves to measure neuroinflammation.

There is currently no way to measure inflammation in the brain’s white matter. Certain PET markers are in development, but they are not considered as usable options in the near future. Furthermore, PET imaging is a highly invasive and expensive way of measuring markers in the body.

Neuro-inflammation measured by free-water imaging based on MRI is a fast and cost-effective method to assess neuroinflammation, and it is available today.

Imeka’s infrastructure is already used in a clinical trial setting. For example, our team has worked on existing databases (ADNI, ADNI+, ADNI2) and significant differences between study groups were observed based on this measure.

Start mapping white matter
inflammation right now

Neuroinflammation is undeniably a subject of great importance, and it will remain so in the foreseeable future. Imeka is currently the only company to offer a solution to map inflammation in the white matter based on its diffusion MRI tools.

Imeka and Pfizer collaboration

Imeka’s expertise with free-water imaging lead to a collaboration with Pfizer, a project that became the subject of an abstract at the 2018 ISMRM conference.

The principle behind the technique

On top of free-water, Imeka can measure intracellular, hindered and extra-cellular water. We assign a constant to CSF (cortico-spinal fluid), to make sure it does not affect our free-water signal.

It’s a simple, yet powerful way of assessing extra-cellular water which can be associated with inflammation.

Time matters

The acquisition time necessary for us to get proper data to perform processing is quite short, in the 5-7 minutes range, for a subject in the MRI.

Legacy dataWe are also able to work with data that was acquired in the past. With a limited amount of directions of acquisition, we can extract significant information from legacy data.

Want to get more out of
past MRI data?

Revealing more with free-water

Free-water imaging can also be used to remove free-water from the signal. This is particularly useful in cases of brain lesions in order to discern what’s hidden within.
The best example? Multiple Sclerosis. We have been able to “track” through lesions by removing the free-water component of the signal.

Differentiating edema from tumour

Another very important aspect of the free-water component for neurosurgeons is that we can help differentiate edema from tumor and from sane tissue in the brain.

Why not turn to NODDI?
The NODDI (neurite orientation dispersion and density imaging) technique uses particularities of MRI’s that are quite advanced, namely multi-shell imaging.
Problem is, most study sites will not be equipped with such technology in the near future. Which means scaling a phase III, worldwide, multi-site clinical trial across different regions becomes impossible unless every site uses high-end MRI.

Imeka can produce comparable results without the need for multi-shell imaging.
Our technology’s acquisition time is shorter, and our sequence can be done on any MRI in the world.

Imeka’s role towards finding a cure to Alzheimer’s
Our current projects in Alzheimer’s are centered on “whole white matter” free-water imaging. Meaning that we average the white matter metrics across the white matter of each brain being studied. Using that technique, we see significant differences between control groups and Alzheimer’s disease groups. However, we do believe that we could be even more precise by looking at specific pathways in the brain, which we can extract thanks to our unique and powerful expertise in fiber tractography and fiber bundling